Analyst Oliver McCammon of LifeSci Capital maintained a Buy rating on Aura Biosciences Inc (AURA – Research Report), retaining the price target of $23.00.
Oliver McCammon has given his Buy rating due to a combination of factors including the promising data from Aura Biosciences’ ongoing Phase 1 trial for their treatment of non-muscle invasive bladder cancer (NMIBC). The recent presentation at the European Association of Urology Congress highlighted the therapy’s clean safety profile and early signs of efficacy, which are crucial indicators of potential success in further clinical trials.
Additionally, the data demonstrated a dual mechanism of action for Aura’s bel-sar, involving both direct tumor cell necrosis and an immune response. The presence of immune cell infiltration in both injected and non-injected tumors suggests a robust immunogenic mechanism, which is promising for the treatment’s effectiveness. The positive clinical responses observed, even at a low dose, support the potential for bel-sar’s further development in bladder cancer and possibly other oncology areas, reinforcing the Buy recommendation.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $22.00 price target.